natgillin/translations-raw huggingface dataset:
Baseline liver function tests should be undertaken in all patients and treatment should not be initiated in patients with baseline values of ALT and/or AST &gt; 3 X upper limit of normal (see section 4.3).
Analüüsid maksafunktsiooni algväärtuse määramiseks tuleb teostada kõikidel patsientidel ning ravi ei tohi alustada kui ALAT´i ja/või ASAT´i algväärtused ületavad 3-kordselt normi ülemise piiri (vt lõik 4.3).
Baseline values of hepatic aminotransferases (aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT) &gt; 3 × ULN) (see sections 4.2 and 4.4).
Maksa aminotransferaaside (aspartaadi aminotransferaas (ASAT) ja/või alaniini aminotransferaas (ALAT) ravieelsed väärtused &gt; 3 x normi ülemise piiri) (vt lõigud 4.2 ja 4.4).
Baseline-adjusted initial PK parameters of VWF and FVIII:C in subjects &lt; 6 (N=9) and 6-12 years old (N=5)
vWF ja FVIII:C algtaseme suhtes korrigeeritud algsed farmakokineetilised parameetrid uuringus osalejatel vanuses &lt; 6 (N = 9) ja 6…12 aastat (N = 5)
BATCH NUMBER, &lt; DONATION AND PRODUCT CODES &gt;
PARTII NUMBER &lt; ANNETUSE KOODID JA TOOTEKOODID &gt;
BATCH NUMBER &lt; , DONATION AND PRODUCT CODES &gt;
PARTII NUMBER &lt; , ANNETUSE JA TOOTEKOODID &gt;
BETWEEN THUMB &amp; MIDDLE FINGER
2/ HOIDKE MIKROSÜSTE SÜSTEEMIGA SÜSTELIT PÖIDLA JA KESKMISE SÕRME
Between weeks 6 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of &gt; 20 weeks.
6. ja 26. nädala vahelisel perioodil psoriaasi sümptomid järk- järgult taastusid ning haiguse taastekke aja mediaan oli &gt; 20 nädala.
Between weeks 6 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of &gt; 20 weeks.
6. ja 26. nädala vahelisel perioodil psoriaasi sümptomid järk- järgult taastusid ning keskmine haiguse taastekke aeg oli &gt; 20 nädala.
Between weeks 6 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of &gt; 20 weeks.
6. ja 26. nädala vahelisel perioodil psoriaasi sümptomid järk-järgult taastusid ning keskmine haiguse taastekke aeg oli &gt; 20 nädala.
BIAL - Portela &amp; Cª , S.A.
BIAL – Portela &amp; Cª , S.A.
BIAL - Portela &amp; Cª , SA
BIAL - Portela &amp; Cª, SA
BIAL - Portela &amp; Cª , SA
BIAL – Portela &amp; Cª, SA
Bial - Portela &amp; Cª., S.A.
Bial - Portela &amp; Cª, S.A.
BIAL -Portela &amp; Cª, S.A.
BIAL – Portela &amp; Cª , S.A.
BIAL, Portela &amp; Ca.
BIAL Portela &amp; Ca.
BIAL-Portela &amp; Cª, S.A.
BIAL – Portela &amp; Cª, SA
Bile acid sequestrants: Because co-administration of bile acid sequestrants may reduce the bioavailability of acidic medicinal products such as nicotinic acid, it is recommended that Pelzont be administered &gt; 1 hour before or &gt; 4 hours after administration of a bile acid sequestrant.
Sapphapete sekvestrandid: Kuna sapphapete sekvestrantide samaaegsel manustamisel võib väheneda happeliste ravimite (sh nikotiinhappe) biosaadavus, on soovitatav Pelzont’i manustada &gt; 1 tund enne või &gt; 4 tundi pärast sapphapete sekvestrandi manustamist.
Bile acid sequestrants: Because co-administration of bile acid sequestrants may reduce the bioavailability of acidic medicinal products such as nicotinic acid, it is recommended that Tredaptive be administered &gt; 1 hour before or &gt; 4 hours after administration of a bile acid sequestrant.
Sapphapete sekvestrandid: Kuna sapphapete sekvestrantide samaaegsel manustamisel võib väheneda happeliste ravimite (sh nikotiinhappe) biosaadavus, on soovitatav Tredaptive’i manustada &gt; 1 tund enne või &gt; 4 tundi pärast sapphapete sekvestrandi manustamist.
Bile acid sequestrants: Because co-administration of bile acid sequestrants may reduce the bioavailability of acidic medicinal products such as nicotinic acid, it is recommended that Trevaclyn be administered &gt; 1 hour before or &gt; 4 hours after administration of a bile acid sequestrant.
Sapphapete sekvestrandid: Kuna sapphapete sekvestrantide samaaegsel manustamisel võib väheneda happeliste ravimite (sh nikotiinhappe) biosaadavus, on soovitatav Trevaclyn’i manustada &gt; 1 tund enne või &gt; 4 tundi pärast sapphapete sekvestrandi manustamist.
Bilirubin &lt; ULN and raised AST
Bilirubiin &lt; normi ülemine piir ja AST kõrgenenud
Bilirubin &lt; 1.25 X upper normal limit
Bilirubiin &lt; 1,25 X ülemine normaalne piir
Biogen Idec (Ireland) Ltd.
Johnson &amp; Johnson Romania S.R.L.
Biogen Netherlands B.V.
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Biogen Sweden AB
UAB "JOHNSON &amp; JOHNSON" filiāle Latvijā
Bleeding episodes related to Paxene were reported in &lt; 3% of patients and bleeding was localised.
Paxene tarvitamisega seotud veritsushäireid esines &lt; 3 % patsientidest, ka oli tegu lokaalsete veritsustega.
Blood and lymphatic system disorders: Thrombocytopenia (In the pooled phase III trials, these events were uncommon (≥ 1/1,000 to &lt; 1/100)).
Vere ja lümfisüsteemi häired: trombotsütopeenia (III faasi uuringute koondandmete alusel esines neid juhte aeg-ajalt (≥ 1/1000 kuni &lt; 1/100)).
Blood glucose decreased ( &lt; 55 mg/dl) 
Alanenud veresuhkur ( &lt; 55 mg/dl) x
Blood glucose decreased ( &lt; 55 mg/dl) 
Alanenud veresuhkur ( &lt; 55 mg/dl)
Blood urea nitrogen &lt; 1.5x upper normal limit
Vere uurea lämmastik &lt; 1,5x ülemine normaalne piir
Blood urea nitrogen &lt; 1.5 X upper normal limit
Vere uurea lämmastik &lt; 1,5x ülemine normaalne piir
Body weight &gt; 40 kg
Kehakaal &gt; 40 kg
Body weight was reduced by 0.4 kg with an estimated treatment difference between Xultophy and insulin degludec of -2.80 kg (p &lt; 0.0001), and the rate of confirmed hypoglycaemia remained 1.8 events per patient year of exposure maintaining a significant reduction in overall risk of confirmed hypoglycaemia compared to insulin degludec.
Kehakaal langes 0,4 kg võrra, hinnanguline ravierinevus Xultophy ja degludek-insuliini vahel oli −2,80 kg (p &lt; 0,0001) ja kinnitatud hüpoglükeemia episoodide arv jäi 1,8 episoodi juurde patsiendi ekspositsiooniaasta kohta, millega saavutati võrreldes degludek-insuliiniga kinnitatud hüpoglükeemia üldriski oluline vähenemine.
Body weight: The mean exposure (AUC) of the active metabolite of prasugrel is approximately 30 to 40% higher in healthy subjects and patients with a body weight of &lt; 60 kg compared to those weighing ≥ 60 kg.
Kehakaal: Prasugreeli aktiivse metaboliidi keskmine ekspositsioon (AUC) on tervetel isikutel ja patsientidel kehakaaluga &lt; 60 kg ligikaudu 30…40 % kõrgem võrreldes ≥ 60 kg kehakaaluga patsientidega.
Boehringer Ingelheim International GmbH Binger Str.
Boehringer Ingelheim International GmbH Boehringer Ingelheim Pharma GmbH &amp; Co.
Boehringer Ingelheim Pharma GmbH &amp; Co. KG Binger Strasse 173
Boehringer Ingelheim Pharma GmbH &amp; Co.
Boehringer Ingelheim RCV GmbH &amp; Co KG
Boehringer Ingelheim RCV GmbH &amp; Co KG organizačná zložka
Boehringer Ingelheim RCV GmbH &amp; Co KG Dr.-Boehringer-Gasse 5-11
Boehringer Ingelheim RCV GmbH &amp; Co KG, Dr.-Boehringer-Gasse 5-11,
Boehringer Ingelheim RCV GmbH &amp; Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCVGmbH &amp; Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH &amp; Co KG Viena – Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH &amp; Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH &amp; Co KG Viena – Sucursala Bucuresti
Boehringer Ingelheim RCVGmbH &amp; Co KG Viena - Sucursala Bucuresti
Bone marrow depression1 including neutropenia ( &lt; 2.0 x 109/l), reticulocytopenia ( &lt; 80 x 109/l), macrocytosis2
Luuüdi depressioon1, sh neutropeenia( &lt; 2,0 x 109/l), retikulotsütopeenia ( &lt; 80 x 109/l), makrotsütoos2
Both phase 3 studiesexcluded patients with uncontrolled hypertension, clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or NYHA Class III or IV heart failure (study 301) or Class II to IV heart failure (study 302) or cardiac ejection fraction measurement of &lt; 50%.
Mõlemast III faasi uuringust jäeti välja patsiendid, kellel oli kontrollimata hüpertensioon, kliiniliselt oluline südamehaigus, mis oli väljendunud müokardiinfarkti või arteriaalsete trombootiliste juhtudena viimase 6 kuu jooksul, raske või ebastabiilne stenokardia või NYHA III või IV klassi südamepuudulikkus (uuring 301) või II kuni IV klassi südamepuudulikkus (uuring 302) või südame väljutusmahu väärtus &lt; 50%.
Both piperaquine and artenimol are highly bound to human plasma proteins: the protein binding observed in in vitro studies was 44-93% for artenimol and &gt; 99% for piperaquine.
Nii piperakviin kui ka artenimool seonduvad tugevalt inimese plasmavalkudega: in vitro uuringutes täheldati seondumist valkudega artenimooli puhul 44–93% ja piperakviini puhul &gt; 99%.
BOTTLE LABEL 5 ml &amp; 10 ml
PUDELI SILT, 5 ml ja 10 ml
Bovine concentrated lactoserum containing specific immunoglobulin G against E. coli F5(K99) adhesin &gt; 2.8 log10/ml
Kontsentreeritud veisepiimaseerum, mis sisaldab spetsiifilisi E. coli F5 (K99) adhesiini vastaseid immuunglobuliine G ≥ 2.8 log10/ml
Bradycardia &lt; 50 beats per minute (bpm)
Bradükardia &lt; 50 lööki minutis.
Bravecto 112.5 mg (2–4.5 kg) Bravecto 250 mg ( &gt; 4.5 –10 kg) Bravecto 500 mg ( &gt; 10 –20 kg) Bravecto 1000 mg ( &gt; 20 –40 kg) Bravecto 1400 mg ( &gt; 40 –56 kg)
Bravecto 112,5 mg (2-4,5 kg) Bravecto 250 mg ( &gt; 4,5-10 kg) Bravecto 500 mg ( &gt; 10-20 kg) Bravecto 1000 mg ( &gt; 20-40 kg) Bravecto 1400 mg ( &gt; 40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs ( &gt; 4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs ( &gt; 10 –20 kg) Bravecto 1000 mg chewable tablets for large dogs ( &gt; 20 –40 kg) Bravecto 1400 mg chewable tablets for very large dogs ( &gt; 40–56 kg)
Bravecto 112,5 mg närimistabletid väga väikestele koertele (2-4,5 kg) Bravecto 250 mg närimistabletid väikestele koertele ( &gt; 4,5-10 kg) Bravecto 500 mg närimistabletid keskmistele koertele ( &gt; 10-20 kg) Bravecto 1000 mg närimistabletid suurtele koertele ( &gt; 20-40 kg) Bravecto 1400 mg närimistabletid väga suurtele koertele ( &gt; 40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs ( &gt; 4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs ( &gt; 10–20 kg) Bravecto 1000 mg chewable tablets for large dogs ( &gt; 20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs ( &gt; 40–56 kg)
Bravecto 112,5 mg närimistabletid väga väikestele koertele (2-4,5 kg) Bravecto 250 mg närimistabletid väikestele koertele ( &gt; 4,5-10 kg) Bravecto 500 mg närimistabletid keskmistele koertele ( &gt; 10-20 kg) Bravecto 1000 mg närimistabletid suurtele koertele ( &gt; 20-40 kg) Bravecto 1400 mg närimistabletid väga suurtele koertele ( &gt; 40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs ( &gt; 4.5–10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs ( &gt; 10–20 kg) Bravecto 1000 mg chewable tablets for large dogs ( &gt; 20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs ( &gt; 40–56 kg)
Bravecto 112,5 mg närimistabletid väga väikestele koertele (2-4,5 kg) Bravecto 250 mg närimistabletid väikestele koertele ( &gt; 4,5-10 kg) Bravecto 500 mg närimistabletid keskmistele koertele ( &gt; 10-20 kg) Bravecto 1000 mg närimistabletid suurtele koertele ( &gt; 20-40 kg) Bravecto 1400 mg närimistabletid väga suurtele koertele ( &gt; 40-56 kg)
Brimica Genuair provided a clinically meaningful improvement in disease-specific health status (as assessed by the St. George’s Respiratory Questionnaire [SGRQ]) in study AUGMENT, with an improvement in the SGRQ total score compared to placebo of -4.35 units (p &lt; 0.0001).
Brimica Genuair parandas kliiniliselt olulisel määral haigusspetsiifilist tervislikku seisundit (nagu hinnati St George haigla hingamisteede küsimustikuga (SGRQ) uuringus AUGMENT, kuna SGRQ järgi paranes koguskoor platseeboga võrreldes -4,35 ühiku võrra (p &lt; 0,0001).
Brinzolamide and N-desethyl-brinzolamide are the predominant components found in the urine along with trace levels ( &lt; 1%) of the N-desmethoxypropyl and O-desmethyl metabolites.
Brinsolamiid ja N-desetüülbrinsolamiid on peamised komponendid uriinis koos N-desmetoksüpropüül- ja O-desmetüülmetaboliitide vähese kogusega ( &lt; 1%)
Bristol-Myers Squibb S.r.l Loc.
Bristol-Myers Squibb GmbH &amp; Co.
Bristol-Myers Squibb Sarl.
Merck Sharp &amp; Dohme d.o.o.
BROADLINE spot-on solution for cats &lt; 2.5 kg BROADLINE spot-on solution for cats 2.5-7.5 kg
BROADLINE täpilahus kassidele &lt; 2,5 kg BROADLINE täpilahus kassidele 2,5-7,5 kg
BROADLINE spot-on solution for cats &lt; 2.5 kg BROADLINE spot-on solution for cats 2.5–7.5 kg
BROADLINE täpilahus kassidele &lt; 2,5 kg BROADLINE täpilahus kassidele 2,5-7,5 kg
BROADLINE spot-on solution for cats &lt; 2.5 kg BROADLINE spot-on solution for cats 2.5–7.5 kg
BROADLINE spot-on solution for cats &lt; 2,5 kg BROADLINE spot-on solution for cats 2,5-7,5 kg
Burning sensation and itching are very common ( 10%).
Väga sageli ( &gt; 10%) esineb põletustunnet ja sügelust.
By 2 years 39%; P &lt; .0001
39%; P &lt; ,0001
By 3 years 50%; P &lt; .0001
50%; P &lt; ,0001
By 4 years 40%; P &lt; .0001
40%; P &lt; ,0001
By 4 years 56%; P &lt; .0001
56%; P &lt; ,0001
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA &lt; 400 copies/ml ( &lt; 50 copies/ml) for REYATAZ + ritonavir were 84% (72%) and for lopinavir + ritonavir were 82% (72%).
Ravivastuse saanud patsientide hulgas, välja arvatud juhud, kui andmed puudusid, moodustasid patsiendid, keda raviti REYATAZ'i + ritonaviiriga ja HIV RNA oli  400 koopiat/ml ( 50 koopiat/ml), proportsionaalselt 84% (72%) ning lopinaviir + ritonaviiri puhul 82% (72%).
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA &lt; 400 copies/ml ( &lt; 50 copies/ml) for REYATAZ + ritonavir were 84% (72%) and for lopinavir + ritonavir were 82% (72%).
Ravivastuse saanud patsientide hulgas, välja arvatud juhud, kui andmed puudusid, moodustasid patsiendid, keda raviti REYATAZ'i + ritonaviiriga ja HIV RNA oli  400 koopiat/ml ( 50 koopiat/ml), proportsionaalselt 84% (72%) ning lopinaviiri + ritonaviiri puhul 82% (72%).
By comparison, vorapaxar exposure (AUC and Cmax) is estimated to be 19-21% lower in patients with a body weight of &gt; 100 kg compared to those weighing 60-100 kg.
Võrdluseks on vorapaksaari ekspositsioon (AUC ja Cmax) hinnanguliselt 19...21% väiksem patsientidel kehakaaluga üle 100 kg kui 60...100 kg kaaluvatel patsientidel.
C 60 mg/m2 i.v., days 22-25, 29-32
22. kuni 25. ja 29. kuni 32. päeval.
c &gt; 48 hours of diarrhoea and/or &gt; 7 days of rash d If patient cannot tolerate 20 mg/day, permanent discontinuation of GIOTRIF should be considered
c &gt; 48 tundi kõhulahtisust ja/või &gt; 7 päeva löövet d Kui patsient ei talu annust 20 mg/päevas, tuleb kaaluda GIOTRIFiga ravi püsivat lõpetamist
c p &lt; 0.001, for each infliximab treatment group vs. control
c p &lt; 0,001, iga infliksimabi grupi puhul vs. kontroll
c p &lt; 0.01 compared with placebo d Patients with Itch NRS &gt; = 4 at baseline: placebo N = 135, Taltz 80 mg Q4W N = 293, Taltz 80 mg Q2W N = 303, Etanercept N = 306
c p &lt; 0,01 võrreldes platseeboga d Patsiendil sügeluse NRS &gt; = 4 lähtemomendil: platseebo N = 135, Taltz 80 mg Q4W N = 293, Taltz 80 mg Q2W N = 303, etanertsept N = 306
C p &lt; 0.05
C p &lt; 0,05
C &amp; M Veterinary Distributors Limited IE-Limerick
Ed13-Piso 1- Esc.3 Quinta da Beloura 2710-693 Sintra
c.1001 G &gt; A
c.979 C &gt; G
c.1012 G &gt; A
c.983 G &gt; C
c.1012 G &gt; T
c.997 C &gt; T
c.1016 T &gt; A
c.1001 G &gt; A
c.1016 T &gt; G
c.998 A &gt; G
c.1018 T &gt; C
c.1012 G &gt; T
c.1028 C &gt; T
c.1012 G &gt; A
c.1033 T &gt; C
c.1016 T &gt; A
c.1046 G &gt; C
c.1028 C &gt; T
c.1055 C &gt; T
c.1033 T &gt; C
c.1061 T &gt; A
c.1046 G &gt; C
c.1066 C &gt; G
c.1055 C &gt; T
c.1066 C &gt; T
c.1061 T &gt; A
c.1067G &gt; A
c.1066 C &gt; G
c.1067G &gt; C
c.1066 C &gt; T
c.1073 A &gt; C
c.1067G &gt; A
c.1073 A &gt; G
c.1067G &gt; C
c.1074 G &gt; T
c.1073 A &gt; C
c.1076 T &gt; C
c.1073 A &gt; G
c.1078 G &gt; A
c.1074 G &gt; T
c.1078 G &gt; T
c.1076 T &gt; C
c.1079 G &gt; A
c.1078 G &gt; A
c.1082 G &gt; A
c.1078 G &gt; T
c.1082 G &gt; C
c.1079 G &gt; A
c.1084 C &gt; A
c.1082 G &gt; A
c.1085 C &gt; T
c.1082 G &gt; C
c.1087 C &gt; T
c.1084 C &gt; A
c.1088 G &gt; A
c.1085 C &gt; T
c.1102 G &gt; A
c.1087 C &gt; T
c.1117 G &gt; A
c.1088 G &gt; A
c.118 C &gt; G
c.71 G &gt; A
c.118 C &gt; T
c.92 C &gt; T
c.1196 G &gt; A or1197 G &gt; A
c.1196 G &gt; A või 1197 G &gt; A
c.140 G &gt; A or 141 G &gt; A
c.140 G &gt; A või 141 G &gt; A
c.156 C &gt; A
c.155 G &gt; A
c.156 C &gt; G
c.156 C &gt; A
c.166 T &gt; G
c.156 C &gt; G
c.167 G &gt; C
c.166 T &gt; G
c.168 C &gt; A
c.167 G &gt; C
c.187 T &gt; C
c.168 C &gt; A
c.188 G &gt; A
c.187 T &gt; C
c.188 G &gt; C
c.188 G &gt; A
c.194 G &gt; T (putative splicing site )
c.194 G &gt; C (oletatav splaissingusait)
c.215 T &gt; G
c.196 G &gt; C
c.218 C &gt; A
c.202 C &gt; T
c.227 T &gt; G
c.215 T &gt; G
c.233 C &gt; G
c.218 C &gt; A
c.235 G &gt; T
c.227 T &gt; G
c.241 T &gt; C
c.233 C &gt; G
c.242 G &gt; A
c.235 G &gt; T
c.242 G &gt; C
c.241 T &gt; C
c.243 G &gt; T
c.242 G &gt; A
c.244 A &gt; T
c.242 G &gt; C
c.256 T &gt; C
c.244 A &gt; T
c.256 T &gt; G
c.243 G &gt; T
c.257 A &gt; G
c.256 T &gt; G
c.258 T &gt; G
c.256 T &gt; C
c.262 T &gt; G
c.257 A &gt; G
c.266 T &gt; C
c.258 T &gt; G
c.266 T &gt; G
c.262 T &gt; G
c.268 T &gt; C
c.266 T &gt; C
c.269 G &gt; A
c.266 T &gt; G
c.270 C &gt; A
c.268 T &gt; C
c.274 G &gt; A
c.270 C &gt; A
c.274 G &gt; C
c.269 G &gt; A
c.274 G &gt; T
c.274 G &gt; C
c.275 A &gt; G
c.274 G &gt; A
c.275 A &gt; T
c.274 G &gt; T
c.277 G &gt; A
c.275 A &gt; G
c.277 G &gt; T
c.275 A &gt; T
c.278 A &gt; G
c.277 G &gt; A
c.278 A &gt; T
c.277 G &gt; T
c.279 C &gt; G
c.278 A &gt; G
c.280T &gt; G
c.278 A &gt; T
c.281 G &gt; A
c.280T &gt; G
c.281 G &gt; C
c.279 C &gt; G
c.284 G &gt; A
c.281 G &gt; C
c.284 G &gt; C
c.284 G &gt; A
c.284 G &gt; T
c.281 G &gt; A
c.295 C &gt; T
c.284 G &gt; T
c.299 G &gt; A
c.284 G &gt; C
c.299 G &gt; C
c.295 C &gt; T
c.305 C &gt; G
c.299 G &gt; A
c.307 G &gt; C
c.299 G &gt; C
c.307 G &gt; T
c.305 C &gt; G
c.317 T &gt; G
c.307 G &gt; C
c.319 C &gt; T
c.307 G &gt; T
c.320 A &gt; T
c.317 T &gt; G
c.334 C &gt; A
c.320 A &gt; T
c.334 C &gt; T
c.319 C &gt; T
c.338 T &gt; C
c.334 C &gt; T
c.350 T &gt; G
c.334 C &gt; A
c.355 C &gt; T
c.338 T &gt; C
c.358 C &gt; G
c.350 T &gt; G
c.359 T &gt; C
c.358 C &gt; G
c.361 G &gt; C
c.[358 C &gt; T; 359 T &gt; C]
c.37 G &gt; C
c.43 G &gt; A
c.371 T &gt; A
c.359 T &gt; C
c.374 A &gt; C
c.361 G &gt; C
c.379 A &gt; T
c.371 T &gt; A
c.386 T &gt; C
c.374 A &gt; C
c.389 A &gt; G
c.379 A &gt; T
c.392 T &gt; C
c.386 T &gt; C
c.394 G &gt; A
c.389 A &gt; G
c.395 G &gt; A
c.392 T &gt; C
c.395 G &gt; C
c.394 G &gt; A
c.398T &gt; A
c.395 G &gt; A
c.400 T &gt; C
c.395 G &gt; C
c.400 T &gt; G
c.398T &gt; A
c.401 A &gt; C
c.400 T &gt; C
c.402 T &gt; G
c.400 T &gt; G
c.406 G &gt; C
c.401 A &gt; C
c.406 G &gt; T
c.402 T &gt; G
c.412 G &gt; A
c.406 G &gt; C
c.413 G &gt; A
c.406 G &gt; T
c.416 A &gt; C
c.412 G &gt; A
c.422 C &gt; A
c.413 G &gt; A
c.422 C &gt; T
c.416 A &gt; C
c.424 T &gt; C
c.422 C &gt; A
c.425 G &gt; A
c.422 C &gt; T
c.426 C &gt; A
c.424 T &gt; C
c.426 C &gt; G
c.425 G &gt; A
c.427 G &gt; C
c.426 C &gt; A
c.43 G &gt; A
c.44 C &gt; G
c.439 G &gt; A
c.426 C &gt; G
c.44 C &gt; G
c.58 G &gt; C
c.440 G &gt; A
c.427 G &gt; C
c.443 G &gt; A
c.439 G &gt; A
c.444 T &gt; G
c.440 G &gt; A
c.453 C &gt; G
c.443 G &gt; A
c.456 C &gt; A
c.444 T &gt; G
c.463 G &gt; C
c.453 C &gt; G
c.467 C &gt; A
c.456 C &gt; A
c.469 C &gt; T
c.463 G &gt; C
c.47 T &gt; C
c.47 T &gt; A
c.484 T &gt; C
c.467 C &gt; A
c.485 G &gt; A
c.469 C &gt; T
c.485 G &gt; T
c.484 T &gt; C
c.486 G &gt; C
c.485 G &gt; A
c.488 G &gt; T
c.485 G &gt; T
c.491 T &gt; G
c.486 G &gt; C
c.493 G &gt; T
c.488 G &gt; T
c.494 A &gt; T
c.491 T &gt; G
c.500 T &gt; A
c.493 G &gt; T
c.500 T &gt; C
c.494 A &gt; T
c.503 A &gt; G
c.500 T &gt; A
c.504 A &gt; C
c.500 T &gt; C
c.508 G &gt; A
c.503 A &gt; G
c.508 G &gt; C
c.504 A &gt; C
c.53 T &gt; C
c.47 T &gt; C
c.547 G &gt; A (putative splicing site )
c.547 G &gt; A (oletatav splaissingusait)
c.559_564 dup
c.560 T &gt; C
c.561 G &gt; T
c.559 A &gt; G
c.58 G &gt; C
c.59 C &gt; A
c.581 C &gt; T
c.559_564 dup
c.584 G &gt; T
M187_S188 dup
c.59 C &gt; A
c.70 T &gt; C
c.593 T &gt; C
c.581 C &gt; T
c.595 G &gt; A
c.584 G &gt; T
c.596 T &gt; G
c.593 T &gt; C
c.599 A &gt; G
c.595 G &gt; A
c.602 C &gt; A
c.599 A &gt; G
c.602 C &gt; T
c.596 T &gt; G
c.608 A &gt; T
c.602 C &gt; T
c.609 G &gt; C
c.602 C &gt; A
c.611 G &gt; A or 612G &gt; A
c.611 G &gt; A või 612G &gt; A
c.613 C &gt; A
c.608 A &gt; T
c.613 C &gt; T
c.609 G &gt; C
c.614 C &gt; T
c.613 C &gt; A
c.619 T &gt; C
c.613 C &gt; T
c.620 A &gt; C
c.614 C &gt; T
c.628 C &gt; T
c.619 T &gt; C
c.629 C &gt; T
c.620 A &gt; C
c.638 A &gt; T
c.628 C &gt; T
c.640 C &gt; T
c.629 C &gt; T
c.641 C &gt; T
c.638 A &gt; T
c.643 A &gt; G
c.640 C &gt; T
c.644 A &gt; G
c.641 C &gt; T
c.647 A &gt; G
c.[644 A &gt; G; 937 G &gt; T]
c.656 T &gt; A
c.646 T &gt; G
c.656 T &gt; C
c.647 A &gt; G
c.659 G &gt; A
c.656 T &gt; A
c.659 G &gt; C
c.656 T &gt; C
c.671 A &gt; G
c.659 G &gt; A
c.673 C &gt; G
c.659 G &gt; C
c.683 A &gt; G
c.671 A &gt; G
c.687 T &gt; A
c.673 C &gt; G
c.688 G &gt; A
c.680 G &gt; A
c.691 G &gt; A
c.680 G &gt; C
c.692 A &gt; G
c.688 G &gt; A
c.692 A &gt; T
c.691 G &gt; A
c.695 T &gt; C
c.683 A &gt; G
c.70 T &gt; C
c.70 T &gt; G
c.70 T &gt; G
c.72 G &gt; C
c.700 G &gt; T
c.692 A &gt; G
c.702 T &gt; G
c.692 A &gt; T
c.71 G &gt; A
c.62 T &gt; C
c.713 G &gt; A
c.687 T &gt; A
c.716 T &gt; C
c.695 T &gt; C
c.72 G &gt; C
c.95 T &gt; C
c.724 A &gt; T
c.713 G &gt; A
c.725 T &gt; A
c.716 T &gt; C
c.728 T &gt; G
c.725 T &gt; A
c.729 G &gt; C
c.724 A &gt; T
c.730 G &gt; A
c.729 G &gt; C
c.730 G &gt; C
c.728 T &gt; G
c.734 G &gt; A or 735G &gt; A
c.734 G &gt; A või 735G &gt; A
c.735 T &gt; G
c.730 G &gt; A
c.740 C &gt; G
c.730 G &gt; C
c.747 C &gt; G
c.735 T &gt; G
c.749 A &gt; C
c.740 C &gt; G
c.758 T &gt; C
c.747 C &gt; G
c.758 T &gt; G
c.749 A &gt; C
c.760-762del GTT
c.758 T &gt; C
c.769 G &gt; C
c.758 T &gt; G
c.770 C &gt; G
c.760-762del GTT
c.772 G &gt; C
c.769 G &gt; C
c.773 G &gt; T
c.770 C &gt; G
c.776 C &gt; G
c.772 G &gt; C
c.776 C &gt; T
c.773 G &gt; T
c.801 G &gt; A (putative splicing site )
c.801 G &gt; A (oletatav splaissingusait)
c.835 C &gt; A
c.826 A &gt; G
c.836 A &gt; G
c.830 G &gt; A
c.837 G &gt; C
c.835 C &gt; A
c.860 G &gt; A or 861G &gt; A
c.860 G &gt; A või 861G &gt; A
c.897 C &gt; G
c.888 G &gt; A
c.898 C &gt; T
c.893 A &gt; G
c.899 T &gt; C
c.897 C &gt; G
c.901 C &gt; G
c.898 C &gt; T
c.902 G &gt; A
c.901 C &gt; G
c.902 G &gt; C
c.899 T &gt; C
c.902 G &gt; T
c.902 G &gt; C
c.908 T &gt; A
c.902 G &gt; A
c.911 G &gt; A
c.902 G &gt; T
c.911 G &gt; C
c.908 T &gt; A
c.919 G &gt; A
c.911 G &gt; A
c.92 C &gt; T
c.62 T &gt; G
c.924 A &gt; T
c.911 G &gt; C
c.925 G &gt; C
c.919 G &gt; A
c.928 C &gt; T
c.924 A &gt; T
c.931 C &gt; G
c.925 G &gt; C
c.935 A &gt; G
c.928 C &gt; T
c.936 G &gt; T
c.931 C &gt; G
c.937 G &gt; T
c.935 A &gt; G
c.938 A &gt; G
c.936 G &gt; T
c.946 G &gt; A
c.937 G &gt; T
c.947 T &gt; G
c.938 A &gt; G
c.95 T &gt; C
c.97 G &gt; T
c.950 T &gt; C
c.946 G &gt; A
c.955 A &gt; T
c.947 T &gt; G
c.956 T &gt; C
c.950 T &gt; C
c.959 A &gt; T
c.955 A &gt; T
c.962 A &gt; G
c.956 T &gt; C
c.962 A &gt; T
c.959 A &gt; T
c.963 G &gt; C
c.962 A &gt; G
c.964 G &gt; C
c.962 A &gt; T
c.966 C &gt; A
c.963 G &gt; C
c.97 G &gt; T
c.98 A &gt; G
c.973 G &gt; A
c.964 G &gt; C
c.973 G &gt; C
c.966 C &gt; A
c.979 C &gt; G
c.973 G &gt; A
c.983 G &gt; C
c.973 G &gt; C
c.983 G &gt; T
c.982 G &gt; T
c.988 C &gt; T
c.983 G &gt; A
c.997 C &gt; T
c.983 G &gt; T
c.998 A &gt; G
c.988 C &gt; T
c.[358 C &gt; T; 359 T &gt; C]
c.355 C &gt; T
c.[644 A &gt; G; 937 G &gt; T]
c.643 A &gt; G
c.G584T
c.572 T &gt; A